UNOS Drops HTLV Screening of Donors: Find out Why

Tuesday, September 28, 2010

Dr. Daniel Kaul, Director of the Transplant Infectious Disease services at the University of Michigan, discusses the changing paradigms for testing of Human T cell lymphotropic viruses. The podcast reviews HTLV disease and epidemiology. Dr. Kaul specifically explains the problems that we have with current testing for HTLV in a low prevalence area such as the United States and the rationale for UNOS deciding to discontinue Donor screening of HTLV

Educational Content Disclaimer: The content, information, opinions, and viewpoints contained in educational materials housed on and linked from the AST web site are those of the authors or contributors of such materials. While the AST and its committees take great care to screen the credentials of the contributors and make every attempt to review the contents, AST MAKES NO WARRANTY, EXPRESSED OR IMPLIED, as to the completeness or accuracy of the content contained in the educational materials or on this website. The reader of these materials uses these materials at his or her own risk, and AST shall not be responsible for any errors, omissions, or inaccuracies in these materials, whether arising through negligence, oversight, or otherwise. Reliance on any information appearing on this site is strictly at your own risk. Read the full disclaimer.